The abstract is read at the publisher; the summary is JClub's.
In 25 patients with locally advanced/metastatic urothelial carcinoma, [68Ga]Ga-DOTA-N188 PET/CT detected primary tumors with higher specificity (86% vs 57%) than [18F]-FDG PET/CT.
- Why it matters: EV and EV plus pembrolizumab are effective but biomarker agnostic, so a whole-body nectin-4 imaging method is needed to characterize target expression beyond FDG.
- What they did: In a prospective, single-center phase 2 feasibility trial, whole-body [68Ga]-N188 PET/CT was compared with [18F]-FDG PET/CT, using conventional CT as the staging reference standard.
- The result: Tracer agreement was weak overall (Spearman r=0.196), with stronger correlation in lymph nodes (r=0.657) and none in primary tumors and bone lesions, supporting complementary rather than interchangeable use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.